内科理论与实践

内科理论与实践 >

2022 , Vol. 17 >Issue 06: 475 - 481

DOI: https://doi.org/10.16138/j.1673-6087.2022.06.011

综述

糖尿病前期“治未病”的几何深度学习与计算医学研究展望

展开
  • 1.上海交通大学医学院附属瑞金医院 a. 中医科；b. 内分泌代谢病科；c. 上海市内分泌代谢病研究所临床研究中心；d. 国家转化医学中心，上海 200025
    2.上海市虹口区疾病预防控制中心，上海 200082
    3.上海市疾病预防控制中心慢病防治科，上海 200051
    4.上海交通大学自然科学研究院，上海 200240
    5.上海国家应用数学中心（上海交通大学分中心），上海 200240

收稿日期: 2022-11-15

  网络出版日期: 2023-02-27

基金资助

转化医学国家重大科技基础设施（上海）开放课题项目(TMSK-2021-506);上海市进一步加快中医药传承创新发展三年行动计划（2021年-2023年）项目(ZY(2021-2023)-0205-01);国家自然科学基金资助项目(32170663);国家自然科学基金资助项目(81270935)

收起

Geometric deep learning and computational medicine research prospects of “preventing disease” in pre diabete

Expand

Received date: 2022-11-15

  Online published: 2023-02-27

Fold

本文引用格式

阮铭, 侯田志超, 王海燕, 黎衍云, 周冰心, 包超慧, 秦洁洁, 王宇光, 方海, 朱伟嵘, 田景琰 . 糖尿病前期“治未病”的几何深度学习与计算医学研究展望[J]. 内科理论与实践, 2022 , 17(06) : 475 -481 . DOI: 10.16138/j.1673-6087.2022.06.011

参考文献

[1] Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin[J]. N Engl J Med, 2002, 346(6): 393-403.
[2] Perreault L, Kahn SE, Christophi CA, et al. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program[J]. Diabetes Care, 2009, 32(9):1583-1588.
[3] Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)[J]. Diabetologia, 2006, 49(2): 289-297.
[4] Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care[J]. Diabetes Care, 2007, 30(3): 753-759.
[5] Forouhi NG, Luan J, Hennings S, et al. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000[J]. Diabet Med, 2007, 24(2):200-207.
[6] Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose[J]. Lancet, 2006, 368(9541): 1096-1105.
[7] Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study[J]. Lancet, 2009, 374(9702): 1677-1686.
[8] Song X, Qiu M, Zhang X, et al. Gender-related affecting factors of prediabetes on its 10-year outcome[J]. BMJ Open Diabetes Res Care, 2016, 4(1): e000169.
[9] Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study[J]. Lancet, 2008, 371(9626): 1783-1789.
[10] Tuomilehto J, Lindstr?m J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance[J]. N Engl J Med, 2001, 344(18): 1343-1350.
[11] Zeng H, Tong R, Tong W, et al. Metabolic biomarkers for prognostic prediction of pre-diabetes: results from a longitudinal cohort study[J]. Sci Rep, 2017, 7(1): 6575.
[12] Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence[J]. J Am Coll Cardiol, 2010, 55(13): 1310-1317.
[13] Magalh?es ME, Cavalcanti BA, Cavalcanti S. Could pre-diabetes be considered a clinical condition? Opinions from an endocrinologist and a cardiologist[J]. Diabetol Metab Syndr, 2010, 2: 2.
[14] Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence[J]. J Am Coll Cardiol, 2010, 55(13): 1310-1317.
[15] Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample[J]. Hypertension, 2006, 47(3): 410-414.
[16] Tian J, Sheng CS, Sun W, et al. Effects of high blood pressure on cardiovascular disease events among Chinese adults with different glucose metabolism[J]. Diabetes Care, 2018, 41(9): 1895-1900.
[17] Park JH, Hong JY, Park YS, et al. Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk[J]. Metabolism, 2021, 123: 154848.
[18] 缪雅, 刘丽丽, 侯田志超, 等. 糖尿病前期人群恶性肿瘤发病风险分析[J]. 内科学理论与实践, 2022, 17(6): 435-440.
[19] Shen B, Li Y, Sheng CS, et al. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer[J]. Lancet Reg Health West Pac, 2022, 30: 100596.
[20] 陈瑜凡, 王燕平, 荣培晶, 等. 糖尿病前期中医证型及证素特点分析[J]. 世界科学技术-中医药现代化, 2022, 24(2): 563-568.
[21] 孙兴利, 谌洪俊, 李鸽, 等. 糖尿病前期人群中医体质调查分析[J]. 贵州中医药大学学报, 2020, 42(5): 96-99.
[22] 李春桂, 曹柏龙, 苗桂珍, 等. 健脾祛湿化痰降浊方为主治疗肥胖型糖尿病前期的临床观察[J]. 陕西中医, 2016, 37(8): 1021-1022.
[23] 吴江雁, 王璇. 中医体质辨识对糖尿病前期的健康干预效果[J]. 新疆中医药, 2019, 37(1): 14-16.
[24] 孙晓娟, 方朝晖. 针灸干预糖尿病前期脾虚痰湿证疗效观察[J]. 中医药临床杂志, 2018, 30(10): 1850-1852.
[25] 王彦军, 焦生林. 穴位埋线治疗2型糖尿病前期患者疗效观察[J]. 上海针灸杂志, 2015, 34(11):1064-1066.
[26] 王金平, 陈燕燕, 巩秋红, 等. 糖尿病和心血管病预防的破冰之旅——大庆糖尿病预防研究30年[J]. 中国科学:生命科学, 2018, 48(8): 902-908.
[27] 李勤, 吴瑞, 王凡, 等. 八段锦对社区糖尿病前期患者干预作用的临床观察[J]. 上海中医药杂志, 2022, 56(5): 49-53.
[28] 张建伟, 吕韶钧, 王继, 等. 太极拳对不同性别2型糖尿病患者治疗效果的比较研究[J]. 北京师范大学学报(自然科学版), 2019, 55(4): 545-550.
[29] Goodfellow I, Bengio Y, Courville A. Deep learning[M]. Cambridge, USA: MIT press, 2016.
[30] LeCun Y, Boser B, Denker J, et al. Handwritten digit recognition with a back-propagation network[J]. Adv Neural Inf Process Syst, 1989, 2: 396-440.
[31] LeCun Y, Bottou L, Bengio Y, et al. Gradient-based learning applied to document recognition[J]. P IEEE, 1998, 86(11):2278-2324.
[32] Bengio Y, LeCun Y. Scaling learning algorithms towards AI[M]// BottouL, ChapelleO, DeCosteD, et al. Large-scale kernel machines, 2007:1-41.
[33] Hinton GE. To recognize shapes, first learn to generate images[J]. Prog Brain Res, 2007, 165: 535-547.
[34] Bronstein MM, Bruna J, LeCun Y, et al. Geometric deep learning: going beyond euclidean data[J]. IEEE Signal Process Mag, 2017, 34(4):18-42.
[35] Wu Z, Pan S, Chen F, et al. A comprehensive survey on graph neural networks[J]. IEEE Trans Neural Netw Learn Syst, 2020, 32(1):4-24.
[36] Zhou J, Cui GQ, Hu SD, et al. Graph neural networks: a review of methods and applications[J]. AI Open, 2020, 1:57-81.
[37] Bronstein MM, Bruna J, Cohen T, et al. Geometric deep learning: grids, groups, graphs, geodesics, and gauges[OL/M]. 2014. https://arxiv.org/pdf/2104.13478.pdf.
[38] Bruna J, Zaremba W, Szlam A, et al. Spectral networks and locally connected networks on graphs[OL/M]. 2013. http://arxiv.org/pdf/1312.6203v3.pdf.
[39] Henaff M, Bruna J, LeCun Y. Deep convolutional networks on graph-structured data[OL/M]. 2015. https://arxiv.org/pdf/1506.05163.pdf.
[40] Defferrard M, Bresson X, Vandergheynst P. Convolutional neural networks on graphs with fast localized spectral filtering[C]. Adv Neural Inf Process Syst, 2016, 29: 3844-3852.
[41] Zheng X, Zhou B, Gao J, et al. How framelets enhance graph neural networks[C]. International Conference on Machine Learning, 2021.
[42] Zheng X, Zhou B, Wang Y, et al. Decimated framelet system on graphs and fast G-framelet transforms[J]. J Mach Learn Res, 2022, 23 (18):1-68.
[43] Zhou B, Jiang Y, Wang Y, et al. Graph neural network for local corruption recovery[EB/C] 2021. https://arxiv.org/pdf/2202.04936v2.pdf.
[44] Zhou B, Liu X, Liu Y, et al. Well-conditioned spectral transforms for dynamic graph representation[C]. Proceedings of the First Learning on Graphs Conference (LoG 2022), 2022.
[45] Jiang X, Zhu R, Li S, et al. Co-embedding of nodes and edges with graph neural networks[J]. IEEE Trans Pattern Anal Mach Intell, 2020.[Epub ahead of print].
[46] Xu K, Hu W, Leskovec J, et al. How powerful are graph neural networks?[C]. International Conference on Learning Representations, 2019.
[47] Xu K, Li CT, Tian YL, et al. Representation learning on graphs with jumping knowledge networks[C]. International Conference on Machine Learning, 2018.
[48] Kipf TN, Welling M. Semi-supervised classi?cation with graph convolutional networks[C]. International Conference on Learning Representations, 2017.
[49] Gilmer J, Schoenholz SS, Riley PF, et al. Neural message passing for quantum chemistry[C]. International Conference on Machine Learning 2017; 1263-1272.
[50] Chen S, Eldar YC, Zhao L. Graph unrolling networks: Interpretable neural networks for graph signal denoising[J]. IEEE Trans Signal Process, 2021, 69: 3699-3713.
[51] Zhu M, Wang X, Shi C, et al. Interpreting and unifying graph neural networks with an optimization framework[C]. Proceedings of the Web Conference, 2021: 1215-1226.
[52] Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold[J]. Nature, 2021, 596(7873):583-589.
[53] Shen Y, Zhou B, Xiong X, et al. How gaph neural networks enhance convolutional neural networks towards mining the topological structures from histology[C]. ICML Workshop on Computational Biology, 2022.
[54] Zhou B, Lv O, Yi K, et al. Lightweight equivariant graph representation learning for protein engineering[EB/C]. 2022. https://ins.sjtu.edu.cn/people/lhong/papers/articles/LGN-NeurIPS2022-Lightweight%20Equivariant%20Graph %20Representation%20Learning%20for%20Protein%20 Engineering.pdf.
[55] Atz K, Grisoni F, Schneider G. Geometric deep learning on molecular representations[J]. Nat Mac Intell, 2021, 3(12): 1023-1032.
[56] Ganea OE, Huang X, Bunne C, et al. Independent SE(3)-equivariant models for end-to-end rigid protein docking[C]. International Conference on Learning Representations, 2022.
[57] Méndez-Lucio O, Ahmad M, del Rio-Chanona EA, et al. A geometric deep learning approach to predict binding conformations of bioactive molecules[J]. Nat Mac Intell, 2021, 3(12):1033-1039.
[58] Fang H, Chen L, Knight JC. From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis[J]. Lancet Rheumatol, 2020, 2: e50-e62.
[59] Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits: from polygenic to omnigenic[J]. Cell, 2017, 169(7): 1177-1186.
[60] De Wolf H, Knezevic B, Burnham KL, et al. A genetics-led approach defines the drug target landscape of 30 immune-related traits[J]. Nat Genet, 2019, 51(7): 1082-1091.
[61] Fang H. PiER: web-based facilities tailored for genetic target prioritisation harnessing human disease genetics, functional genomics and protein interactions[J]. Nucleic Acids Res, 2022, 50(W1):W583-W592.
[62] Fang H, Xu Y. Priority index: database of genetic targets in immune-mediated disease[J]. Nucleic Acids Res, 2022, 50(D1): D1358-D1367.
[63] Robertson CC, Inshaw JRJ, Onengut-Gumuscu S, et al. Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes[J]. Nat Genet, 2021, 53(7): 962-971.
Options
文章导航

/

〈 〉